June 10, 2009


Novus signs agreement with Chr Hansen
Press Release

NOVUS International, Inc. and Chr. Hansen, Inc., two leaders in animal health and nutrition, signed an agreement at the World Pork Expo, combining the strengths of both organisations with respect to sales and technical competencies to position BioPlus 2B to the swine industry in the US.


BioPlus 2B, a direct fed microbial (DFM), contains two strains of Bacillus (Bacillus licheniformis and Bacillus subtilis). These Bacillus strains can improve the intestinal microbial balance of swine. Safety studies have proven that BioPlus 2B strains are totally safe to animals and humans. The data was compiled into more than 5,000 pages to get final approval in the EU for all swine categories, making BioPlus 2B the most extensively documented microbial for swine.


''This partnership compliments our GEMS nutrition programme and gut health management portfolio,'' stated Dan Meagher, Vice President, Americas.


BioPlus 2B helps balance bacterial populations in the intestinal tract to improve performance regardless of life stage. BioPlus 2B is a DFM that increases live weight gain and improves feed conversion efficiency when used in nursery and grow-finish applications. BioPlus 2B also helps improve overall intestinal health, improved average daily gain (ADG) and decreased mortality.


''The cooperation with NOVUS International immediately broadens our access to the swine market in the US. We expect strong growth in sales with this cooperation'', explains Dr. Bill Braman, VP Marketing and Sales Animal Health & Nutrition, Chr. Hansen NA.


St. Louis, Missouri-based Novus International, Inc. produces animal nutrition and health products and serves customers in more than 80 countries around the world.


Chr. Hansen is a global biotechnology company that provides ingredients to the food, dairy, human health and nutrition, and animal health industries. The company is a leading supplier of cultures, probiotics, enzymes and natural colours.